{"id":751610,"date":"2023-04-26T17:02:42","date_gmt":"2023-04-26T21:02:42","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/agex-therapeutics-receives-stock-exchange-deficiency-letter-2\/"},"modified":"2023-04-26T17:02:42","modified_gmt":"2023-04-26T21:02:42","slug":"agex-therapeutics-receives-stock-exchange-deficiency-letter-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/agex-therapeutics-receives-stock-exchange-deficiency-letter-2\/","title":{"rendered":"AgeX Therapeutics Receives Stock Exchange Deficiency Letter"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>AgeX Therapeutics Receives Stock Exchange Deficiency Letter<\/b><\/p>\n<p>ALAMEDA, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.agexinc.com&amp;esheet=53387974&amp;newsitemid=20230426005312&amp;lan=en-US&amp;anchor=AgeX+Therapeutics&amp;index=1&amp;md5=6d0d885569e95d5b70f800729a65ef17\">AgeX Therapeutics <\/a>, Inc. (\u201cAgeX\u201d; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on April 20, 2023 it received a letter (the \u201cDeficiency Letter\u201d) from the staff of the NYSE American (the \u201cExchange\u201d) indicating that AgeX does not meet certain of the Exchange\u2019s continued listing standards as set forth in Sections 1003(a)(i), (ii), and (iii) of the Exchange Company Guide in that AgeX has stockholders equity of less than (A) $2,000,000 and has incurred losses from continuing operations and\/or net losses during its two most recent fiscal years, (B) $4,000,000 and has incurred losses from continuing operations and\/or net losses during three out of four of its most recent fiscal years, and (C) $6.0 million or more and has reported losses from continuing operations and\/or net losses in its five most recent fiscal years. The Deficiency Letter states that as AgeX remains subject to the conditions set forth in prior letters from the Exchange with respect to AgeX\u2019s deficiencies in stockholders equity, and if AgeX is not in compliance with all of the Exchange\u2019s stockholders equity standards, or does not make progress consistent with AgeX\u2019s Exchange approved plan to come into compliance with the Exchange\u2019s continued listing standards, by May 17, 2023, the Exchange will initiate delisting proceedings as appropriate. AgeX may appeal a staff delisting determination in accordance with Section 1010 and Part 12 of the Exchange Company Guide.<\/p>\n<p>\nAgeX intends to make arrangements to have its common stock quoted on an electronic interdealer quotation system if its common stock is delisted from the Exchange.<\/p>\n<p><b>About AgeX Therapeutics<\/b><\/p>\n<p>\nAgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics to treat human diseases to increase healthspan and combat the effects of aging. AgeX\u2019s PureStem<sup>\u00ae<\/sup> and UniverCyte\u2122 manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeX\u2019s revolutionary longevity platform induced Tissue Regeneration (iTR\u2122) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. HyStem<sup>\u00ae<\/sup> is AgeX\u2019s delivery technology to stably engraft PureStem or other cell therapies in the body. AgeX is seeking opportunities to establish licensing and collaboration arrangements around its broad IP estate and proprietary technology platforms and therapy product candidates.<\/p>\n<p>\nFor more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.agexinc.com&amp;esheet=53387974&amp;newsitemid=20230426005312&amp;lan=en-US&amp;anchor=www.agexinc.com&amp;index=2&amp;md5=1d4a3e251e442cf51eff01cd1d555e80\">www.agexinc.com<\/a> or connect with the company on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fagexthera&amp;esheet=53387974&amp;newsitemid=20230426005312&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=438bda063141d927306bc3c91cc08e60\">Twitter<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fagextherapeutics&amp;esheet=53387974&amp;newsitemid=20230426005312&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=4&amp;md5=b7181227b5497347e7277367ce17e470\">LinkedIn<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2Fagexthera&amp;esheet=53387974&amp;newsitemid=20230426005312&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=13f102b0d6bd76c0fd3d5c6f67f2e642\">Facebook<\/a>, and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2Fc%2FAgeXTherapeuticsInc&amp;esheet=53387974&amp;newsitemid=20230426005312&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=77edfe502f4103af1744643c9511c05f\">YouTube<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nCertain statements contained in this release are \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as \u201cwill,\u201d \u201cbelieves,\u201d \u201cplans,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cestimates\u201d should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the \u201cRisk Factors\u201d section of AgeX\u2019s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (a copy of which may be obtained at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=53387974&amp;newsitemid=20230426005312&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=b7fddbc5a15f3f52e81c85ef121510de\">www.sec.gov<\/a>). Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230426005312r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230426005312\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230426005312\/en\/<\/a><\/span><\/p>\n<p>\nAndrea E. Park<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:apark@agexinc.com\">apark@agexinc.com<br \/>\n<\/a><br \/>(510) 671-8620<\/p>\n<p><b>KEYWORDS:<\/b> California United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research Diabetes Health Technology Stem Cells Biotechnology Alternative Medicine Health Pharmaceutical Science<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230426005312\/en\/1404785\/3\/AGEX_logo_400x400.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>AgeX Therapeutics Receives Stock Exchange Deficiency Letter ALAMEDA, Calif.&#8211;(BUSINESS WIRE)&#8211;AgeX Therapeutics , Inc. (\u201cAgeX\u201d; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on April 20, 2023 it received a letter (the \u201cDeficiency Letter\u201d) from the staff of the NYSE American (the \u201cExchange\u201d) indicating that AgeX does not meet certain of the Exchange\u2019s continued listing standards as set forth in Sections 1003(a)(i), (ii), and (iii) of the Exchange Company Guide in that AgeX has stockholders equity of less than (A) $2,000,000 and has incurred losses from continuing operations and\/or net losses during its two most recent fiscal years, (B) $4,000,000 and has incurred losses from continuing operations and\/or net losses during three out &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/agex-therapeutics-receives-stock-exchange-deficiency-letter-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AgeX Therapeutics Receives Stock Exchange Deficiency Letter&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-751610","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AgeX Therapeutics Receives Stock Exchange Deficiency Letter - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/agex-therapeutics-receives-stock-exchange-deficiency-letter-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AgeX Therapeutics Receives Stock Exchange Deficiency Letter - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AgeX Therapeutics Receives Stock Exchange Deficiency Letter ALAMEDA, Calif.&#8211;(BUSINESS WIRE)&#8211;AgeX Therapeutics , Inc. (\u201cAgeX\u201d; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on April 20, 2023 it received a letter (the \u201cDeficiency Letter\u201d) from the staff of the NYSE American (the \u201cExchange\u201d) indicating that AgeX does not meet certain of the Exchange\u2019s continued listing standards as set forth in Sections 1003(a)(i), (ii), and (iii) of the Exchange Company Guide in that AgeX has stockholders equity of less than (A) $2,000,000 and has incurred losses from continuing operations and\/or net losses during its two most recent fiscal years, (B) $4,000,000 and has incurred losses from continuing operations and\/or net losses during three out &hellip; Continue reading &quot;AgeX Therapeutics Receives Stock Exchange Deficiency Letter&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/agex-therapeutics-receives-stock-exchange-deficiency-letter-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-26T21:02:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230426005312r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agex-therapeutics-receives-stock-exchange-deficiency-letter-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agex-therapeutics-receives-stock-exchange-deficiency-letter-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AgeX Therapeutics Receives Stock Exchange Deficiency Letter\",\"datePublished\":\"2023-04-26T21:02:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agex-therapeutics-receives-stock-exchange-deficiency-letter-2\\\/\"},\"wordCount\":685,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agex-therapeutics-receives-stock-exchange-deficiency-letter-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230426005312r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agex-therapeutics-receives-stock-exchange-deficiency-letter-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agex-therapeutics-receives-stock-exchange-deficiency-letter-2\\\/\",\"name\":\"AgeX Therapeutics Receives Stock Exchange Deficiency Letter - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agex-therapeutics-receives-stock-exchange-deficiency-letter-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agex-therapeutics-receives-stock-exchange-deficiency-letter-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230426005312r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-04-26T21:02:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agex-therapeutics-receives-stock-exchange-deficiency-letter-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agex-therapeutics-receives-stock-exchange-deficiency-letter-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agex-therapeutics-receives-stock-exchange-deficiency-letter-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230426005312r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230426005312r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agex-therapeutics-receives-stock-exchange-deficiency-letter-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AgeX Therapeutics Receives Stock Exchange Deficiency Letter\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AgeX Therapeutics Receives Stock Exchange Deficiency Letter - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/agex-therapeutics-receives-stock-exchange-deficiency-letter-2\/","og_locale":"en_US","og_type":"article","og_title":"AgeX Therapeutics Receives Stock Exchange Deficiency Letter - Market Newsdesk","og_description":"AgeX Therapeutics Receives Stock Exchange Deficiency Letter ALAMEDA, Calif.&#8211;(BUSINESS WIRE)&#8211;AgeX Therapeutics , Inc. (\u201cAgeX\u201d; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on April 20, 2023 it received a letter (the \u201cDeficiency Letter\u201d) from the staff of the NYSE American (the \u201cExchange\u201d) indicating that AgeX does not meet certain of the Exchange\u2019s continued listing standards as set forth in Sections 1003(a)(i), (ii), and (iii) of the Exchange Company Guide in that AgeX has stockholders equity of less than (A) $2,000,000 and has incurred losses from continuing operations and\/or net losses during its two most recent fiscal years, (B) $4,000,000 and has incurred losses from continuing operations and\/or net losses during three out &hellip; Continue reading \"AgeX Therapeutics Receives Stock Exchange Deficiency Letter\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/agex-therapeutics-receives-stock-exchange-deficiency-letter-2\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-26T21:02:42+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230426005312r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agex-therapeutics-receives-stock-exchange-deficiency-letter-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agex-therapeutics-receives-stock-exchange-deficiency-letter-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AgeX Therapeutics Receives Stock Exchange Deficiency Letter","datePublished":"2023-04-26T21:02:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agex-therapeutics-receives-stock-exchange-deficiency-letter-2\/"},"wordCount":685,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agex-therapeutics-receives-stock-exchange-deficiency-letter-2\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230426005312r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agex-therapeutics-receives-stock-exchange-deficiency-letter-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/agex-therapeutics-receives-stock-exchange-deficiency-letter-2\/","name":"AgeX Therapeutics Receives Stock Exchange Deficiency Letter - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agex-therapeutics-receives-stock-exchange-deficiency-letter-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agex-therapeutics-receives-stock-exchange-deficiency-letter-2\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230426005312r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-04-26T21:02:42+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agex-therapeutics-receives-stock-exchange-deficiency-letter-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/agex-therapeutics-receives-stock-exchange-deficiency-letter-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agex-therapeutics-receives-stock-exchange-deficiency-letter-2\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230426005312r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230426005312r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agex-therapeutics-receives-stock-exchange-deficiency-letter-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AgeX Therapeutics Receives Stock Exchange Deficiency Letter"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751610","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=751610"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751610\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=751610"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=751610"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=751610"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}